Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.53 0.92 (4.26%) Market Cap: 1.60 Bil Enterprise Value: 1.33 Bil PE Ratio: 204.82 PB Ratio: 3.69 GF Score: 62/100

Kiniksa Pharmaceuticals Ltd at Bank of America Biotech SMID Cap Conference Transcript

Dec 07, 2022 / 03:15PM GMT
Release Date Price: $15.34 (-0.13%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Okay. Good morning. Welcome to the BofA SMID Cap Biotech Conference. My name is Geoff Meacham, I'm the Senior of Biopharma analyst, and welcome to the morning sessions. We're thrilled to have with us Kiniksa. Speaking on behalf of Kiniksa is CEO, Sanj Patel. Sanj, how are you?

Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

I'm fairly well, how are you, Geoff?

Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Good. Good to see your face. Next year, maybe we'll do this in person. So let's just kick it off real quick. I know you're an efficient guy, so let's just go and give us a 30,000-foot view here of a quick background and then get right into some questions on our (inaudible) a lot of stuff.

Sanj K. Patel
Kiniksa Pharmaceuticals, Ltd. - CEO & Chairman of the Board

Absolutely. So again, thanks for having me here, Geoff.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot